Stryker to invest about $400 million in CMR Surgical and take exclusive U.S. rights to Versius

Stryker said Monday it will put about $400 million of preferred equity into CMR Surgical and become the exclusive U.S. seller of CMR's Versius soft-tissue surgical robot, with an option to buy the company later.

What Stryker is putting up

Stryker said Monday it will invest about $400 million, or £300 million, of preferred equity in CMR Surgical, a privately held Cambridge, U.K., robotics company. The money is meant to fund further work on CMR's Versius soft-tissue surgical robot and its commercial rollout, and the investment is still subject to customary closing conditions.

The preferred stake also gives Stryker an exclusive option to buy all of CMR's outstanding equity later, on terms set in the agreement. Separately, Stryker will be the exclusive U.S. sales agent for the Versius portfolio, while CMR keeps leading product development and sales outside the United States. Andy Pierce, Stryker's group president for MedSurg and Neurotechnology, is expected to join CMR's board.

That package is an alliance and an option, not a completed takeover of CMR. Stryker said the transaction still needs regulatory approvals and customary closing conditions.

Why Stryker wants soft-tissue robotics

Stryker already sells surgical equipment, endoscopy and visualization tools, and its Mako system for orthopedic robotics. Soft-tissue surgery — procedures in the abdomen and other cavities rather than joints — is a different market that the company has been circling for years.

Pierce called soft-tissue robotics a "high-growth adjacency" and a "thoughtful and disciplined entry," and said Stryker picked CMR because Versius can help hospitals and ambulatory surgery centers expand robotic programs across a range of procedures. CMR chief executive Massimiliano Colella said the investment strengthens CMR's ability to innovate and grow globally, and that Stryker's U.S. reach is a significant opportunity.

Where Versius stands in the U.S.

Versius is already used internationally for soft-tissue procedures. In the United States, CMR's next-generation Versius Plus system received FDA 510(k) clearance in December 2025 for cholecystectomy, or gallbladder removal, in adults. MassDevice reported that clearance at the time and said U.S. commercialization was planned for 2026. CMR's clearance materials say additional U.S. indications are being advanced; Monday's announcement does not name them.

Stryker's release describes Versius as a modular, second-generation platform designed to fit existing operating-room workflows. Neither company disclosed CMR's revenue, valuation for a full buyout under the option, or a timetable for exercising that option.

Scale for Stryker shareholders

Stryker closed Friday at $277.33 and was trading near $275.59 in the early Monday session, with a market value of about $105.7 billion, according to public market data. The $400 million preferred investment is less than half a percent of that market value — a TickerGrove calculation — so the near-term balance-sheet impact is modest. The strategic question is whether the U.S. agency role and the exclusive buyout option give Stryker a workable path into soft-tissue robotics without an all-cash acquisition today.

Why it matters for investors

For Stryker investors, Monday's deal is a defined entry into a segment the company has talked about for years, with a capped cash outlay and a future option rather than an immediate full purchase. For hospitals watching the robotics market, it pairs a large U.S. medtech sales force with a platform that already has a gallbladder clearance and a broader soft-tissue ambition.